Table 5.
Total number of complications (grouped according to the targeting method).
| References | Neurological | Minor/Treatment Related | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sensory | Ataxia/gait disturbance | Motor | Speech and swallowing | Headache and fatigue | Sonication related | Frame and MRI related | Other | |||||||||||||||||
| A | B | C | A | B | C | A | B | C | A | B | C | A | B | C | A | B | C | A | B | C | A | B | C | |
| Atlas based targeting | ||||||||||||||||||||||||
| Lipsman et al. (24) | 2 | 1 | NA | 0 | 0 | NA | 0 | 0 | NA | 0 | 0 | NA | 0 | 0 | NA | 0 | 0 | NA | 0 | 0 | NA | 1 Deep Vein Thrombosis | 1 Deep Vein Thrombosis | NA |
| Elias et al. (25) | 15 | 4 | 4 | 10 | 5 | 0 | 1 (Grip) | 1 (5 days) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 33 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 0 |
| Chang et al. (26) | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 3 failed to attain temperature above 50 °C | 0 | 0 |
| Gallay et al. (27) | 0 | 0 | 0 | 5 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Elias et al. (47) (Treatment group) | 27 | 17 | 10 | 32 | 17 | 8 | 2 (Grip) | 2 (Grip) | 1 (Grip) | 2 | 2 | 2 | 11 | 3 | 2 | 54 | 0 | 0 | 17 | 0 | 0 | 0 | 0 | 0 |
| Elias et al. (47) (Sham Crossover) | 13 | 8 | 8 | 14 | 7 | 4 | 3 (Grip) | 2 (Grip) | 1 (Grip) | 3 | 2 | 2 | 11 | 2 | 2 | 16 | 0 | 0 | 7 | 0 | 0 | 0 | 0 | 0 |
| Chang et al. (48) | NA | NA | 1 | NA | NA | 12 | NA | NA | 1 | NA | NA | 0 | NA | NA | 0 | NA | NA | 0 | NA | NA | 0 | NA | NA | 0 |
| Halpern et al. (49) | NA | NA | 12 | NA | NA | 10 | NA | NA | 2 | NA | NA | 1 | NA | NA | 1 | NA | NA | 0 | NA | NA | 0 | NA | NA | 1-slow movements |
| Zaroor et al. (28)# | 4 | 4 | 0 | 9 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 39 | 0 | 0 | 8 | 8 | 0 | 0 | 0 | 0 |
| Schreglmann et al. (29) | 0 | 0 | 0 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Kim et al. (30) | 1 | 1 | 0 | 1 | 1 | 0 | 2 (Facial) | 2 (Facial- one resolved in 1 month) | 1 (Facial) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Federau et al. (32) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Jung et al. (33) | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Iacopino et al. (34)# | 2 | 0 | 0 | 6 | 3 | 2 | 1 (Grip) | 1 (Grip - 1 week) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 6 | 0 | 0 | 4 ET patients - aborted treatment due to severe headache; 1 ET patient - failed to attain ablative temperature | 0 | 0 |
| Boutet et al. (36) | 12 | 5 | NA | 62 | 20 | NA | 13 | 6 | NA | 3 | 3 | NA | 0 | 0 | NA | NA | NA | NA | NA | NA | NA | 0 | 0 | NA |
| Park et al. (37) | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hori et al. (38) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Jones et al. (40) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Sinai et al. (41) | 11 | 11 | 5 | 24 | 24 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 0 | 65 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Chang et al. (42) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Krishna et al. (44) (Pivotal) | NA | NA | 42 | NA | NA | 59 | NA | NA | 4 mild, 2 moderate | NA | NA | 5 | NA | NA | 0 | NA | NA | 0 | NA | NA | 0 | NA | NA | 6 mild, 3 moderate |
| Krishna et al. (44) (Post Pivotal) | NA | NA | 56 | NA | NA | 89 | NA | NA | 16 mild | NA | NA | 17 | NA | NA | 0 | NA | NA | 0 | NA | NA | 0 | NA | NA | 16 mild, 2 moderate |
| Gallay et al. (45) | 1 | 1 | 1 | 7 | 5 | 5 | 0 | 0 | 0 | 5 | 1 | 1 | 0 | 0 | 0 | 4 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Paff et al. (51) | 0 | 0 | 0 | 1 | 1 | 0 | 1 (c/l lower limb) | 1 (c/l lower limb) (1 m) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fukutome et al. (46) | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 90 | 54 | 140 | 178 | 104 | 194 | 23 | 15 | 28 | 14 | 8 | 28 | 30 | 9 | 5 | 251 | 0 | 0 | 55 | 10 | 0 | 9 | 1 | 28 |
| DTI based targeting | ||||||||||||||||||||||||
| Chazen et al. (31) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Krishna et al. (35) | 0 | 1 | 0 | 4 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pineda-Pardo et al. (39) | 4 | 4 | 4 | 7 | 7 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Yang et al. (50) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Miller et al. (43) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Buch et al. (52) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Total | 4 | 5 | 4 | 11 | 10 | 2 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Studies reporting zero complications are marked as “0.” Studies in which no complication data was reported for respective time period are marked as “NA.”
A, immediate (during treatment to within 48 h); B, short term (48 h−3 months); C, long term (persisting for more than 3 months). Period in brackets denotes time until when the complication persisted.
#
Complications not mentioned separately for ET patients.